147 related articles for article (PubMed ID: 36442832)
1. Lost Therapeutic Benefit of Delayed Low-Density Lipoprotein Cholesterol Control in Statin-Treated Patients and Cost-Effectiveness Analysis of Lipid-Lowering Intensification.
Marquina C; Morton J; Zomer E; Talic S; Lybrand S; Thomson D; Liew D; Ademi Z
Value Health; 2023 Apr; 26(4):498-507. PubMed ID: 36442832
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of ezetimibe treatment in combination with statin therapy in the United States.
Davies GM; Vyas A; Baxter CA
J Med Econ; 2017 Jul; 20(7):723-731. PubMed ID: 28426345
[TBL] [Abstract][Full Text] [Related]
3. Comparison of Evolocumab and Ezetimibe, Both Combined with Statin Therapy, for Patients with Recent Acute Coronary Syndrome: A Cost-Effectiveness Analysis from the Chinese Healthcare Perspective.
Xi X; Wang X; Xie W; Jia Y; Sanchez SZ; Martinez L; Zhao Q
Cardiovasc Drugs Ther; 2023 Oct; 37(5):905-916. PubMed ID: 35467312
[TBL] [Abstract][Full Text] [Related]
4. A systematic review and economic evaluation of statins for the prevention of coronary events.
Ward S; Lloyd Jones M; Pandor A; Holmes M; Ara R; Ryan A; Yeo W; Payne N
Health Technol Assess; 2007 Apr; 11(14):1-160, iii-iv. PubMed ID: 17408535
[TBL] [Abstract][Full Text] [Related]
5. Changes in LDL-C levels and goal attainment associated with addition of ezetimibe to simvastatin, atorvastatin, or rosuvastatin compared with titrating statin monotherapy.
Foody JM; Toth PP; Tomassini JE; Sajjan S; Ramey DR; Neff D; Tershakovec AM; Hu H; Tunceli K
Vasc Health Risk Manag; 2013; 9():719-27. PubMed ID: 24265554
[TBL] [Abstract][Full Text] [Related]
6. Cost-Effectiveness of Icosapent Ethyl, Evolocumab, Alirocumab, Ezetimibe, or Fenofibrate in Combination with Statins Compared to Statin Monotherapy.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Clin Drug Investig; 2022 Aug; 42(8):643-656. PubMed ID: 35819632
[TBL] [Abstract][Full Text] [Related]
7. Cost-Effectiveness of Lipid-Lowering Treatments in Young Adults.
Kohli-Lynch CN; Bellows BK; Zhang Y; Spring B; Kazi DS; Pletcher MJ; Vittinghoff E; Allen NB; Moran AE
J Am Coll Cardiol; 2021 Nov; 78(20):1954-1964. PubMed ID: 34763772
[TBL] [Abstract][Full Text] [Related]
8. Therapeutic practice patterns related to statin potency and ezetimibe/simvastatin combination therapies in lowering LDL-C in patients with high-risk cardiovascular disease.
Toth PP; Foody JM; Tomassini JE; Sajjan SG; Ramey DR; Neff DR; Tershakovec AM; Hu XH; Tunceli K
J Clin Lipidol; 2014; 8(1):107-16. PubMed ID: 24528691
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of Low-density Lipoprotein Cholesterol Level-Guided Statin Treatment in Patients With Borderline Cardiovascular Risk.
Kohli-Lynch CN; Bellows BK; Thanassoulis G; Zhang Y; Pletcher MJ; Vittinghoff E; Pencina MJ; Kazi D; Sniderman AD; Moran AE
JAMA Cardiol; 2019 Oct; 4(10):969-977. PubMed ID: 31461121
[TBL] [Abstract][Full Text] [Related]
10. Inclisiran as Adjunct Lipid-Lowering Therapy for Patients with Cardiovascular Disease: A Cost-Effectiveness Analysis.
Kam N; Perera K; Zomer E; Liew D; Ademi Z
Pharmacoeconomics; 2020 Sep; 38(9):1007-1020. PubMed ID: 32789593
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of adding ezetimibe to atorvastatin vs switching to rosuvastatin therapy in Portugal.
Laires PA; Ejzykowicz F; Hsu TY; Ambegaonkar B; Davies G
J Med Econ; 2015; 18(8):565-72. PubMed ID: 25788039
[TBL] [Abstract][Full Text] [Related]
12. Lipid-Lowering Strategies for Primary Prevention of Coronary Heart Disease in the UK: A Cost-Effectiveness Analysis.
Morton JI; Marquina C; Lloyd M; Watts GF; Zoungas S; Liew D; Ademi Z
Pharmacoeconomics; 2024 Jan; 42(1):91-107. PubMed ID: 37606881
[TBL] [Abstract][Full Text] [Related]
13. Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering.
Pletcher MJ; Lazar L; Bibbins-Domingo K; Moran A; Rodondi N; Coxson P; Lightwood J; Williams L; Goldman L
Ann Intern Med; 2009 Feb; 150(4):243-54. PubMed ID: 19221376
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial.
Pearson T; Denke M; McBride P; Battisti WP; Brady WE; Palmisano J
Am J Geriatr Pharmacother; 2005 Dec; 3(4):218-28. PubMed ID: 16503317
[TBL] [Abstract][Full Text] [Related]
15. Projected cost-effectiveness of ezetimibe/simvastatin compared with doubling the statin dose in the United Kingdom: findings from the INFORCE study.
Reckless J; Davies G; Tunceli K; Hu XH; Brudi P
Value Health; 2010; 13(6):726-34. PubMed ID: 20561328
[TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease.
Schlackow I; Kent S; Herrington W; Emberson J; Haynes R; Reith C; Collins R; Landray MJ; Gray A; Baigent C; Mihaylova B;
Kidney Int; 2019 Jul; 96(1):170-179. PubMed ID: 31005271
[TBL] [Abstract][Full Text] [Related]
17. Cost effectiveness of ezetimibe in patients with cardiovascular disease and statin intolerance or contraindications: a Markov model.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Rees A; Wilkinson A; Durrington P; Chilcott J
Am J Cardiovasc Drugs; 2008; 8(6):419-27. PubMed ID: 19159125
[TBL] [Abstract][Full Text] [Related]
18. Health economic evaluation of screening and treating children with familial hypercholesterolemia early in life: Many happy returns on investment?
Ademi Z; Norman R; Pang J; Liew D; Zoungas S; Sijbrands E; Ference BA; Wiegman A; Watts GF
Atherosclerosis; 2020 Jul; 304():1-8. PubMed ID: 32526542
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness of Lipid-Lowering Therapies for Cardiovascular Prevention in Germany.
Michaeli DT; Michaeli JC; Boch T; Michaeli T
Cardiovasc Drugs Ther; 2023 Aug; 37(4):683-694. PubMed ID: 35015186
[TBL] [Abstract][Full Text] [Related]
20. Estimating the health benefits and costs associated with ezetimibe coadministered with statin therapy compared with higher dose statin monotherapy in patients with established cardiovascular disease: results of a Markov model for UK costs using data registries.
Ara R; Pandor A; Tumur I; Paisley S; Duenas A; Williams R; Wilkinson A; Durrington P; Chilcott J
Clin Ther; 2008 Aug; 30(8):1508-23. PubMed ID: 18803993
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
